Last 12 months
Inside the activity.
1 purchase rows · 28 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 15 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 7 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2021 Filed Dec 9, 2021 21:43 UTC |
HEWSON MARILLYN ADirector
|
GrantDeferred Share Units · Derivative | 210.608 | $161.67 | $34,049.00 |
DisclosureSEC source: 0001225208-21-014716 · doc4.xml · derivative · entry 1 HEWSON MARILLYN A · CIK 0001217496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,030.367 Underlying: Common Stock · 210.608 shares Expires not disclosed F1 · derivative.exercise_price: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 21:43 UTC |
Washington A. EugeneDirector
|
GrantDeferred Share Units · Derivative | 350.841 | $161.67 | $56,720.46 |
DisclosureSEC source: 0001225208-21-014717 · doc4.xml · derivative · entry 1 Washington A. Eugene · CIK 0001561989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,558.9293 Underlying: Common Stock · 350.841 shares Expires not disclosed F1 · derivative.exercise_price: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 21:43 UTC |
WEINBERGER MARK ADirector
|
GrantDeferred Share Units · Derivative | 242.126 | $161.67 | $39,144.51 |
DisclosureSEC source: 0001225208-21-014718 · doc4.xml · derivative · entry 1 WEINBERGER MARK A · CIK 0001785997 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,113.753 Underlying: Common Stock · 242.126 shares Expires not disclosed F1 · derivative.exercise_price: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:37 UTC |
HEWSON MARILLYN ADirector
|
GrantDeferred Share Units · Derivative | 193.912 | $174.53 | $33,843.46 |
DisclosureSEC source: 0001225208-21-012177 · doc4.xml · derivative · entry 1 HEWSON MARILLYN A · CIK 0001217496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,819.759 Underlying: Common Stock · 193.912 shares Expires not disclosed F1 · derivative.exercise_price: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:37 UTC |
Washington A. EugeneDirector
|
GrantDeferred Share Units · Derivative | 323.028 | $174.53 | $56,378.08 |
DisclosureSEC source: 0001225208-21-012178 · doc4.xml · derivative · entry 1 Washington A. Eugene · CIK 0001561989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,208.0883 Underlying: Common Stock · 323.028 shares Expires not disclosed F1 · derivative.exercise_price: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 20:37 UTC |
WEINBERGER MARK ADirector
|
GrantDeferred Share Units · Derivative | 222.932 | $174.53 | $38,908.32 |
DisclosureSEC source: 0001225208-21-012179 · doc4.xml · derivative · entry 1 WEINBERGER MARK A · CIK 0001785997 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,871.627 Underlying: Common Stock · 222.932 shares Expires not disclosed F1 · derivative.exercise_price: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| June 09, 2021 Filed Feb 16, 2022 01:03 UTC |
Ullmann Michael HExec VP, General Counsel
|
GiftCommon Stock | 608 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002216 · doc4.xml · nonDerivative · entry 2 Ullmann Michael H · CIK 0001537710 · Exec VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,321.882 F1 · price: Gift Read SEC document |
| June 09, 2021 Filed Feb 16, 2022 01:03 UTC |
Ullmann Michael HExec VP, General Counsel
|
GiftCommon Stock | 304 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002216 · doc4.xml · nonDerivative · entry 1 Ullmann Michael H · CIK 0001537710 · Exec VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,929.882 F1 · price: Gift Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 20:49 UTC |
HEWSON MARILLYN ADirector
|
GrantDeferred Share Units · Derivative | 203.239 | $165.46 | $33,627.92 |
DisclosureSEC source: 0001225208-21-009206 · doc4.xml · derivative · entry 1 HEWSON MARILLYN A · CIK 0001217496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,625.847 Underlying: Common Stock · 203.239 shares Expires not disclosed F1 · derivative.exercise_price: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 20:50 UTC |
Washington A. EugeneDirector
|
GrantDeferred Share Units · Derivative | 338.567 | $165.46 | $56,019.30 |
DisclosureSEC source: 0001225208-21-009207 · doc4.xml · derivative · entry 1 Washington A. Eugene · CIK 0001561989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,885.0603 Underlying: Common Stock · 338.567 shares Expires not disclosed F1 · derivative.exercise_price: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 20:50 UTC |
WEINBERGER MARK ADirector
|
GrantDeferred Share Units · Derivative | 226.087 | $165.46 | $37,408.36 |
DisclosureSEC source: 0001225208-21-009208 · doc4.xml · derivative · entry 1 WEINBERGER MARK A · CIK 0001785997 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,648.695 Underlying: Common Stock · 226.087 shares Expires not disclosed F1 · derivative.exercise_price: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:07 UTC |
HEWSON MARILLYN ADirector
|
GrantDeferred Share Units · Derivative | 210.858 | $157.66 | $33,243.87 |
DisclosureSEC source: 0001225208-21-005122 · doc4.xml · derivative · entry 1 HEWSON MARILLYN A · CIK 0001217496 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,422.608 Underlying: Common Stock · 210.858 shares Expires not disclosed F1 · derivative.exercise_price: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:07 UTC |
Washington A. EugeneDirector
|
GrantDeferred Share Units · Derivative | 345.32 | $157.66 | $54,443.15 |
DisclosureSEC source: 0001225208-21-005123 · doc4.xml · derivative · entry 1 Washington A. Eugene · CIK 0001561989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,546.4933 Underlying: Common Stock · 345.32 shares Expires not disclosed F1 · derivative.exercise_price: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:07 UTC |
WEINBERGER MARK ADirector
|
GrantDeferred Share Units · Derivative | 210.858 | $157.66 | $33,243.87 |
DisclosureSEC source: 0001225208-21-005124 · doc4.xml · derivative · entry 1 WEINBERGER MARK A · CIK 0001785997 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,422.608 Underlying: Common Stock · 210.858 shares Expires not disclosed F1 · derivative.exercise_price: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: The Deferred Share Units acquired, and dividends accrued, under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each Deferred Share Unit representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Duato JoaquinVice Chair, Exec Committee
|
Exercise / conversionRestricted Share Units · Derivative | 5,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002849 · doc4.xml · derivative · entry 7 Duato Joaquin · CIK 0001673401 · Vice Chair, Exec Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. F2 · derivative.expiration_date: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Duato JoaquinVice Chair, Exec Committee
|
Exercise / conversionPerformance Share Units · Derivative | 27,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002849 · doc4.xml · derivative · entry 6 Duato Joaquin · CIK 0001673401 · Vice Chair, Exec Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,738 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Duato JoaquinVice Chair, Exec Committee
|
Tax withholdingCommon Stock | 11,931 | $165.55 | $1,975,177.05 |
DisclosureSEC source: 0001225208-21-002849 · doc4.xml · nonDerivative · entry 4 Duato Joaquin · CIK 0001673401 · Vice Chair, Exec Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,052 F4 · shares: Shares withheld for payment of taxes upon vesting of Performance Share Units. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Duato JoaquinVice Chair, Exec Committee
|
Tax withholdingCommon Stock | 1,507 | $165.55 | $249,483.85 |
DisclosureSEC source: 0001225208-21-002849 · doc4.xml · nonDerivative · entry 3 Duato Joaquin · CIK 0001673401 · Vice Chair, Exec Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,983 F3 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Duato JoaquinVice Chair, Exec Committee
|
Exercise / conversionCommon Stock | 5,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002849 · doc4.xml · nonDerivative · entry 2 Duato Joaquin · CIK 0001673401 · Vice Chair, Exec Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Duato JoaquinVice Chair, Exec Committee
|
Exercise / conversionCommon Stock | 27,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002849 · doc4.xml · nonDerivative · entry 1 Duato Joaquin · CIK 0001673401 · Vice Chair, Exec Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Fasolo PeterExec VP, Chief HR Officer
|
Exercise / conversionRestricted Share Units · Derivative | 2,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002850 · doc4.xml · derivative · entry 6 Fasolo Peter · CIK 0001509999 · Exec VP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,060 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. F2 · derivative.expiration_date: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Fasolo PeterExec VP, Chief HR Officer
|
Exercise / conversionPerformance Share Units · Derivative | 10,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002850 · doc4.xml · derivative · entry 5 Fasolo Peter · CIK 0001509999 · Exec VP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Fasolo PeterExec VP, Chief HR Officer
|
Tax withholdingCommon Stock | 4,935 | $165.55 | $816,989.25 |
DisclosureSEC source: 0001225208-21-002850 · doc4.xml · nonDerivative · entry 4 Fasolo Peter · CIK 0001509999 · Exec VP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,343.0055 F4 · shares: Shares withheld for payment of taxes upon vesting of Performance Share Units. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Fasolo PeterExec VP, Chief HR Officer
|
Tax withholdingCommon Stock | 761 | $165.55 | $125,983.55 |
DisclosureSEC source: 0001225208-21-002850 · doc4.xml · nonDerivative · entry 3 Fasolo Peter · CIK 0001509999 · Exec VP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,278.0055 F3 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Fasolo PeterExec VP, Chief HR Officer
|
Exercise / conversionCommon Stock | 2,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002850 · doc4.xml · nonDerivative · entry 2 Fasolo Peter · CIK 0001509999 · Exec VP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,039.0055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Fasolo PeterExec VP, Chief HR Officer
|
Exercise / conversionCommon Stock | 10,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002850 · doc4.xml · nonDerivative · entry 1 Fasolo Peter · CIK 0001509999 · Exec VP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,979.0055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
McEvoy AshleyEVP, WW Chair, Medical Devices
|
Exercise / conversionRestricted Share Units · Derivative | 2,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002851 · doc4.xml · derivative · entry 8 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,102 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. F2 · derivative.expiration_date: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
McEvoy AshleyEVP, WW Chair, Medical Devices
|
Exercise / conversionPerformance Share Units · Derivative | 11,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002851 · doc4.xml · derivative · entry 7 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,034 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
McEvoy AshleyEVP, WW Chair, Medical Devices
|
Tax withholdingCommon Stock | 4,090 | $165.55 | $677,099.50 |
DisclosureSEC source: 0001225208-21-002851 · doc4.xml · nonDerivative · entry 4 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,155.9545 F4 · shares: Shares withheld for payment of taxes upon vesting of Performance Share Units. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
McEvoy AshleyEVP, WW Chair, Medical Devices
|
Tax withholdingCommon Stock | 588 | $165.55 | $97,343.40 |
DisclosureSEC source: 0001225208-21-002851 · doc4.xml · nonDerivative · entry 3 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,245.9545 F3 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
McEvoy AshleyEVP, WW Chair, Medical Devices
|
Exercise / conversionCommon Stock | 2,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002851 · doc4.xml · nonDerivative · entry 2 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,833.9545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
McEvoy AshleyEVP, WW Chair, Medical Devices
|
Exercise / conversionCommon Stock | 11,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002851 · doc4.xml · nonDerivative · entry 1 McEvoy Ashley · CIK 0001745936 · EVP, WW Chair, Medical Devices 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,731.9545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Sneed Michael EEVP, Global Corp Aff & CCO
|
Exercise / conversionRestricted Share Units · Derivative | 1,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002852 · doc4.xml · derivative · entry 8 Sneed Michael E · CIK 0001745939 · EVP, Global Corp Aff & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,474 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. F2 · derivative.expiration_date: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Sneed Michael EEVP, Global Corp Aff & CCO
|
Exercise / conversionPerformance Share Units · Derivative | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002852 · doc4.xml · derivative · entry 7 Sneed Michael E · CIK 0001745939 · EVP, Global Corp Aff & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,737 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Sneed Michael EEVP, Global Corp Aff & CCO
|
Tax withholdingCommon Stock | 2,676 | $165.55 | $443,011.80 |
DisclosureSEC source: 0001225208-21-002852 · doc4.xml · nonDerivative · entry 4 Sneed Michael E · CIK 0001745939 · EVP, Global Corp Aff & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,177 F4 · shares: Shares withheld for payment of taxes upon vesting of Performance Share Units. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Sneed Michael EEVP, Global Corp Aff & CCO
|
Tax withholdingCommon Stock | 437 | $165.55 | $72,345.35 |
DisclosureSEC source: 0001225208-21-002852 · doc4.xml · nonDerivative · entry 3 Sneed Michael E · CIK 0001745939 · EVP, Global Corp Aff & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,853 F3 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Sneed Michael EEVP, Global Corp Aff & CCO
|
Exercise / conversionCommon Stock | 1,474 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002852 · doc4.xml · nonDerivative · entry 2 Sneed Michael E · CIK 0001745939 · EVP, Global Corp Aff & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Sneed Michael EEVP, Global Corp Aff & CCO
|
Exercise / conversionCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002852 · doc4.xml · nonDerivative · entry 1 Sneed Michael E · CIK 0001745939 · EVP, Global Corp Aff & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Stoffels PaulusVice Chair, Exec Committee
|
Exercise / conversionRestricted Share Units · Derivative | 5,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002853 · doc4.xml · derivative · entry 6 Stoffels Paulus · CIK 0001559387 · Vice Chair, Exec Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,610 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. F2 · derivative.expiration_date: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Stoffels PaulusVice Chair, Exec Committee
|
Exercise / conversionPerformance Share Units · Derivative | 29,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002853 · doc4.xml · derivative · entry 5 Stoffels Paulus · CIK 0001559387 · Vice Chair, Exec Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,452 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Stoffels PaulusVice Chair, Exec Committee
|
Tax withholdingCommon Stock | 12,725 | $165.55 | $2,106,623.75 |
DisclosureSEC source: 0001225208-21-002853 · doc4.xml · nonDerivative · entry 4 Stoffels Paulus · CIK 0001559387 · Vice Chair, Exec Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,547.3732 F4 · shares: Shares withheld for payment of taxes upon vesting of Performance Share Units. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Stoffels PaulusVice Chair, Exec Committee
|
Tax withholdingCommon Stock | 1,592 | $165.55 | $263,555.60 |
DisclosureSEC source: 0001225208-21-002853 · doc4.xml · nonDerivative · entry 3 Stoffels Paulus · CIK 0001559387 · Vice Chair, Exec Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,272.3732 F3 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Stoffels PaulusVice Chair, Exec Committee
|
Exercise / conversionCommon Stock | 5,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002853 · doc4.xml · nonDerivative · entry 2 Stoffels Paulus · CIK 0001559387 · Vice Chair, Exec Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,864.3732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Stoffels PaulusVice Chair, Exec Committee
|
Exercise / conversionCommon Stock | 29,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002853 · doc4.xml · nonDerivative · entry 1 Stoffels Paulus · CIK 0001559387 · Vice Chair, Exec Committee 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,254.3732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Taubert Jennifer LEVP, WW Chair, Pharmaceuticals
|
Exercise / conversionRestricted Share Units · Derivative | 2,177 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002854 · doc4.xml · derivative · entry 6 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,177 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. F2 · derivative.expiration_date: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Taubert Jennifer LEVP, WW Chair, Pharmaceuticals
|
Exercise / conversionPerformance Share Units · Derivative | 11,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002854 · doc4.xml · derivative · entry 5 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Taubert Jennifer LEVP, WW Chair, Pharmaceuticals
|
Tax withholdingCommon Stock | 5,268 | $165.55 | $872,117.40 |
DisclosureSEC source: 0001225208-21-002854 · doc4.xml · nonDerivative · entry 4 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,126.001 F4 · shares: Shares withheld for payment of taxes upon vesting of Performance Share Units. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Taubert Jennifer LEVP, WW Chair, Pharmaceuticals
|
Tax withholdingCommon Stock | 797 | $165.55 | $131,943.35 |
DisclosureSEC source: 0001225208-21-002854 · doc4.xml · nonDerivative · entry 3 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,394.001 F3 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Taubert Jennifer LEVP, WW Chair, Pharmaceuticals
|
Exercise / conversionCommon Stock | 2,177 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002854 · doc4.xml · nonDerivative · entry 2 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,191.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
| February 12, 2021 Filed Feb 18, 2021 00:09 UTC |
Taubert Jennifer LEVP, WW Chair, Pharmaceuticals
|
Exercise / conversionCommon Stock | 11,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002854 · doc4.xml · nonDerivative · entry 1 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,014.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 12, 2018; converted into shares of Common Stock upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.